Search

Your search keyword '"Magro A"' showing total 121 results

Search Constraints

Start Over You searched for: Author "Magro A" Remove constraint Author: "Magro A" Journal gastroenterology Remove constraint Journal: gastroenterology
121 results on '"Magro A"'

Search Results

1. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

2. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

3. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

4. Mo1518: EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN’S DISEASE: RESULTS FROM THE STARDUST TRIAL

5. Mo1519: CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

6. Su1531: SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS

7. Mo1847 THE INFLUENCE OF PERSISTENT ACTIVE INFLAMMATION ON IFX PHARMACOKINETIC MODELING AND DISEASE PROGRESSION ASSESSMENT: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY IN INFLAMMATORY BOWEL DISEASE PATIENTS

11. Challenges and Opportunities in IBD Clinical Trial Design

12. Mo1519: CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

13. Su1531: SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS

14. Mo1518: EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN’S DISEASE: RESULTS FROM THE STARDUST TRIAL

15. Sa073 USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

16. 105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

17. Su446 PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

19. Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease

21. Aminosalicylates and COVID-19: Facts or Coincidences?

25. Su1224 DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES

26. Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization

27. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

28. Sa1867 LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL SHORTENING ARE NOT PREDICTIVE OF SUCCESS OF THE INTERVENTION

29. Tu1870 C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2

30. Tu1864 ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST INTERIM ANALYSIS

32. 105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

33. Su446 PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

34. Sa073 USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

35. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

36. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

37. Sa1867 LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL SHORTENING ARE NOT PREDICTIVE OF SUCCESS OF THE INTERVENTION

39. Tu1870 C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2

40. Tu1864 ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST INTERIM ANALYSIS

41. Mo1868 – Methylation Patterns in Dysplasia in Inflammatory Bowel Disease Patients

42. Sa1867 – Sexual Quality of Life in Inflammatory Bowel Disease – a Multicentre, National-Level Study

43. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn’s Disease

44. Mo1868 – Methylation Patterns in Dysplasia in Inflammatory Bowel Disease Patients

45. Sa1867 – Sexual Quality of Life in Inflammatory Bowel Disease – a Multicentre, National-Level Study

47. Su1801 - Different Histological Indexes for the Assessment of Ulcerative Colitis Activity

48. Su1801 - Different Histological Indexes for the Assessment of Ulcerative Colitis Activity

Catalog

Books, media, physical & digital resources